Introduction {#s1}
============

Lung cancer, accounting for 13% (1.6 million) of the total cases and 18% (1.4 million) of the deaths, was the most commonly diagnosed cancer as well as the leading cause of cancer death worldwide in 2008 [@pone.0060107-Jemal1]. Benefiting from the tobacco control, lung cancer death rate is decreasing in western developed countries. However, it is increasing in developing countries such as China, where smoking prevalence is still increasing [@pone.0060107-Jemal1]. Non-small cell lung cancer, accounting for 80% of primary lung carcinomas, was the most common type with a 5-year survival rate ranging from 2 to 47% for different clinical stages and histopathology [@pone.0060107-Risch1]. About twenty percent of NSCLC patients are suitable for surgery at the time of diagnosis, and the other 80%, receiving conventional chemoradiation, can only survive a short period of time [@pone.0060107-Schiller1]. Therefore, the early diagnosis is essential to the prolonged survival of this disease.

Tumor suppressor gene promoter methylation is considered as an important mechanism for its inactivation, which occurs in the early stage of the tumorigenesis for many types of cancer [@pone.0060107-Risch1], [@pone.0060107-Belinsky1]. Thus, detection of aberrant methylation of tumor suppressor genes could be a potential method for the early diagnosis of various types of cancer, including NSCLC. The aberrant methylation status of primary tumors can be detected by methylation specific PCR(MSP), which could detect one methylated allele in the presence of 10^3^--10^4^ unmethylated alleles [@pone.0060107-Herman1]. And many studies have also shown that cancer-specific methylation of tumor suppressor genes can be found in autologous clinical samples such as plasma, serum, sputum or bronchoalveolar lavage fluid(BALF) of NSCLC, indicating that it can be potential biomarkers for non-invasive diagnosis of this disease [@pone.0060107-ZochbauerMuller1]--[@pone.0060107-Wang1]. But the frequency of DNA methylation in tumor suppressor genes between cancer tissue and autologous clinical samples ranged a lot among the published studies with small sample size. Accordingly, we performed a meta-analysis on the basis of published articles of *P^16INK4a^* promoter methylation and lung cancer in order to better identify the correlation of methylation status between cancer tissue and autologous samples.

Materials and Methods {#s2}
=====================

Studies Identification {#s2a}
----------------------

The selection procedure of studies was illustrated in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement flow chart ([Fig. 1](#pone-0060107-g001){ref-type="fig"}). Studies about *P^16INK4a^* gene promoter methylation in NSCLC, published before January 2012, were identified through an electronic sensitive search of Medline, EMBSE and CNKI databases. The searching strategy was performed using "Non-Small-Cell Lung Carcinoma" AND "methylation" as the Medical Subject Headings (MeSH) and corresponding free text word searching term. The title and abstract of initial identified articles were evaluated for appropriateness to the inclusion criteria. Then all potentially relevant articles were assessed in full-text paper and all references of included articles were further scanned for additional analysis.

![PRISMA flowchart of the literature search strategy for systematic review.\
(Data from some studies was used more than once, as they reported data in multiple controls.).](pone.0060107.g001){#pone-0060107-g001}

Data Extraction and Quality Assessment {#s2b}
--------------------------------------

The inclusion criteria of the meta-analysis was as follows: the patients were limited to non-small cell lung carcinoma without restriction of stages. The methods used for methylation detection were confined to methylation-specific polymerase chain reaction(MSP), real-time MSP(RT-MSP) and quantitative MSP(q-MSP). The results were the *P^16INK4A^* gene promoter methylation status in tumor tissue and corresponding autologous controls, including non-tumor lung tissue(NLT), plasma, sputum and bronchoalveolar lavage fluid(BALF) of NSCLC patients. Information on the name of the first author, year of publication, region of the included subjects and methylation status of *P^16INK4A^* gene in cancer tissue and controls were recorded from each study. Detailed information about each article was extracted by two reviewers (JG and YW) and then checked by the third reviewer (SZ) as described in the Cochrane Handbook for systematic reviews [@pone.0060107-Higgins1].

Statistical Analysis {#s2c}
--------------------

STATA/SE 11.0 (StataCorp LP, <http://www.stata.com>) and MetaAanlyst 3.13 (<http://www.biomedcentral.com>) were used for statistical analysis. Methylation status in tumor tissue and controls was calculated as methylation rate. The odds of *P^16INK4A^* promoter methylation in lung cancer tissue versus autologous controls was expressed as the odds ratio (OR) and its 95% confidence intervals (CI). Statistical heterogeneity across studies was assessed by chi-square (χ^2^) test [@pone.0060107-DerSimonian1], and the inconsistency was calculated by I^2^ [@pone.0060107-Higgins2]. If heterogeneity was significant (χ^2^, *p*\<0.1 or I^2^\>50%), meta-regression analysis was employed for further evaluation of the source of heterogeneity. And subgroup analysis according to the source of heterogeneity was performed for further evaluation. Finally, if significant heterogeneity across studies was detected and no appropriate clinical explanation of the heterogeneity was found, the random-effect method (Dersimonian-Laird method) was used to pool the data. Inversely, without significant heterogeneity between studies, fixed-effect method was purchased. And sensitivity analysis was also performed to assess the contribution of each study to the final results of the meta-analysis. The Begger's funnel plot and Egger's test were used to evaluate the possible publication bias [@pone.0060107-Egger1]. The correlation of *P^16INK4A^* gene promoter methylation between tumor tissue and autologous clinical control samples were compared by Spearman's rank correlation test.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

A total of three hundred and ninety-four studies were initially identified by searching the electronic databases. And 268 potential applicable articles, published from 2000 and 2012, were retrieved in full-text. Of those, 234 studies were excluded for the reasons: about other genes methylation status without *P^16INK4A^*, duplicated publication, no appropriate outcome data, about cell lines, about animals, without proper controls. Finally, thirty-four studies [@pone.0060107-ZochbauerMuller1]--[@pone.0060107-Wang1], [@pone.0060107-Seike1]--[@pone.0060107-Sun1] that reported data of methylation frequency in non-small-cell lung carcinoma tissue, and autologous controls were finally pooled in the meta-analysis ([Fig. 1](#pone-0060107-g001){ref-type="fig"}). Of the 34 included articles, 25 were conducted in Asia-Pacific(18 in Chinese mainland, 3 in Taiwan, 1 in Hong Kong, 2 in Korea, 1 in Japan), 4 in USA and 5 in Europe (3 in Italy, 1 in Greece, 1in England). Some of the included studies reported methylation status separately according to gender, histopathology types, smoking status and tumor stages. The general characteristics of included studies were summarized in [table 1](#pone-0060107-t001){ref-type="table"}.

10.1371/journal.pone.0060107.t001

###### General characteristics of included studies.

![](pone.0060107.t001){#pone-0060107-t001-1}

                                                                                           Sample size (n)         Histology   Control type            
  -------------------------------------------- ------ ----------- -------------- -------- ----------------- ----- ----------- -------------- ---- ---- --------------
  Seike [@pone.0060107-Seike1]                  2000     Japan     63.7(40--80)    15/6          21          21       MSP           9         12   0        NLT
  Su [@pone.0060107-Su1]                        2000     China         58.9         Na           72          10       MSP           39        31   2        NLT
  He [@pone.0060107-He1]                        2001     China          Na          Na           30          30       MSP           17        11   2        NLT
  Zochbauer [@pone.0060107-ZochbauerMuller1]    2001      USA           Na        76/31          107         104      MSP           43        45   19       NLT
  Bearzatto [@pone.0060107-Bearzatto1]          2002     Italy          64         28/7          35          35     RT-MSP          10        18   7       Plasm
  Chen [@pone.0060107-Chen1]                    2002    Taiwan          Na          Na           67          21       MSP           Na        Na   Na      Sputum
  He [@pone.0060107-He2]                        2002     China          Na          Na           21          21       MSP           12        9    0        BALF
  Ng [@pone.0060107-Ng1]                        2002   Hong Kong       60.2        25/8          33          33       MSP           13        15   5     Plasm,BALF
  Cai [@pone.0060107-Cai1]                      2003     China         59.5       46/23          69          69       MSP           25        36   8       Plasm
  Harden [@pone.0060107-Harden1]                2003      USA       67(40--87)    50/40          90          90      q-MSP          33        36   21       NLT
  Liu [@pone.0060107-Liu2]                      2003     China          Na          Na           98          110      MSP           58        40   0    Plasm sputum
  Guo [@pone.0060107-Guo1]                      2004      USA      66.1(42--83)     Na           20          20       MSP           1         18   1      NLT BLAF
  Liu [@pone.0060107-Liu1]                      2004     China          Na          Na           40          40       MSP           23        17   0       Plasm
  Zhang [@pone.0060107-Zhang2]                  2004     China          Na          Na           40          40       MSP           23        14   3        NLT
  Russo [@pone.0060107-Russo1]                  2005      USA           Na          Na           48          48       MSP           Na        Na   Na      Plasm
  Georgiou [@pone.0060107-Georgiou1]            2007    Greece      63(38--76)     32/3          35          35       MSP           15        17   3      NLT BALF
  Li [@pone.0060107-Li1]                        2006     China          Na        38/11          49          49       MSP           22        24   3       Plasm
  Rosalia [@pone.0060107-Cirincione1]           2006     Italy     60.2(51--74)    20/9          29          18       MSP           5         23   1       Sputum
  Ulivi [@pone.0060107-Ulivi1]                  2006     Italy          Na        49/12          61          61     RT-MSP          16        36   9       Plasm
  Wang [@pone.0060107-Wang2]                    2006     China        32--73       42/5          47          47       MSP           31        7    9        NLT
  Belinsky [@pone.0060107-Belinsky2]            2007    England     62(37--80)    49/23          72          72       MSP           22        29   21   Plasm Sputum
  Hong [@pone.0060107-Hong1]                    2007     Korea          Na        63/18          81          81     RT-MSP          40        34   7        NLT
  Hsu(1) [@pone.0060107-Hsu1]                   2007    Taiwan          69        45/18          63          63      q-MSP          41        13   9     NLT Plasm
  Hsu(2) [@pone.0060107-Hsu2]                   2007    Taiwan          Na          Na           82          82       MSP           37        23   22    NLTSputum
  Kim [@pone.0060107-Kim1]                      2007     Korea        63±8.4      80/19          99          99       MSP           61        38   0        NLT
  Yang [@pone.0060107-Yang1]                    2007     China      56(31--77)    34/15          49          49       MSP           26        23   0        NLT
  Zhang [@pone.0060107-Zhang3]                  2007     China          Na          Na           29          29       MSP           7         16   6        NLT
  Guo [@pone.0060107-GuoX1]                     2008     China        59±13       72/34          106         106      MSP           41        27   39      Plasm
  Wang [@pone.0060107-Wang1]                    2008     China          Na        17/11          28          18       MSP           7         15   6        NLT
  Chen [@pone.0060107-Chen2]                    2010     China     59.7(32--79)   102/18         120         120      MSP           66        26   28    NLT Plasm
  Guo [@pone.0060107-Guo2]                      2010     China         59.2        23/5          28          28       MSP           Na        Na   Na       NLT
  Zhang [@pone.0060107-Zhang4]                  2006     China     52.3(37--73)   33/15          48          48       MSP           25        20   3        NLT
  Zhang [@pone.0060107-Zhang1]                  2011     China      61(32--79)    162/38         200         200      MSP          104        59   37       NLT
  Sun [@pone.0060107-Sun1]                      2012     China          65        96/24          120         120      MSP           32        72   16      Sputum

M = male; F = female; T = tumor; C = control; Sq = squamous cell carcinoma; Ad = adenocarcinoma; Ots = others; BALF = bronchoalveolar lavage; NLT:non-tumor lung issue; Na = not available.

Pooled Results from the Meta-analysis {#s3b}
-------------------------------------

In the meta-analysis, data from 2 652 non-small cell lung cancer patients including 5 175 samples were pooled with an odds ratio of 3.45 (95% CI: 2.63--4.54) in tumor tissue versus autologous controls under random-effect method ([Fig. 2](#pone-0060107-g002){ref-type="fig"}). The sensitivity analysis indicated that the odds ratio range from 3.28(95% CI: 2.52--4.28) to 3.57(95% CI: 2.72--4.68) by omitting a single study under the random-effect model ([Fig. 3](#pone-0060107-g003){ref-type="fig"}). Only very slight change of odds ratio was seen in the sensitivity analysis, which demonstrated that the pooled odds ratio was not sensitive to a single study.

![Forest plot of *P^16INK4A^* promoter methylation in cancer tissue versus autologous controls.\
The squares and horizontal lines represent the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the pooled OR and 95% CI.](pone.0060107.g002){#pone-0060107-g002}

![The sensitivity analysis by omitting a single study under the random-effect method.\
The circles and horizontal lines represents the pooled OR and 95% CI by omitting a certain study. The area of the circles reflects the weight (by sample size). The diamond represents the pooled OR and 95% CI by including all of studies.](pone.0060107.g003){#pone-0060107-g003}

Meta-regression and Subgroup Analysis {#s3c}
-------------------------------------

As the significant heterogeneity was found across the studies (I^2^ = 69.8%, χ^2^ = 135.7, *P*\<0.0001), the meta-regression was performed for further evaluation of the source of heterogeneity with the Knapp-Hartung modification method. We assumed the heterogeneity may arise from the control types, age of the subjects, ethnicity of the patients, histology types, smoking status, tumor stages, sample size and the methods of methylation detection. However, complete subtype data can be only obtained in the control types, ethnicity, sample size and methylation detection methods. So, the regression was carried out by including each of complete subtypes data in the covariates. In the results of the meta-regression, no source of significant heterogeneity was found in all of them except for the control type (coefficient = −0.36, *P* = 0.018, [Table 2](#pone-0060107-t002){ref-type="table"}). The τ^2^ decreased from 0.48 to 0.37, which indicates 23% \[(0.48--0.37)/0.48\] of heterogeneity can be explained by different control types. However, the adjustment for all the other factors with complete data mentioned above reduced the residual variance across studies only by 6%, which indicates that different ethnicity, sample size and methylation detection methods can explain only a slight proportion of the heterogeneity among studies. But for conservative, we still performed subgroup analysis according to the potential heterogeneity sources. In the subgroup analysis, the significant odds of the *P^16INK4A^* promoter methylation in tumor tissue was only changed in non-smokers (OR = 4.53, 95% CI: 0.68--30.26, *P* = 0.120) and sputum autologous control (OR = 1.49, 95% CI: 0.86--2.57, *P* = 0.151, [Table 3](#pone-0060107-t003){ref-type="table"}). However, the changed of results should be interpreted with caution as only a small subject was included in non-smokers and sputum control subgroup analysis ([Table 3](#pone-0060107-t003){ref-type="table"}).

10.1371/journal.pone.0060107.t002

###### Meta-regression analysis.

![](pone.0060107.t002){#pone-0060107-t002-2}

  Heterogeneity sources        Coef.(95%CI)          t       p     τ^2^   I^2^ Res(%)   R^2^(%) Adjusted
  ----------------------- ----------------------- ------- ------- ------ ------------- ------------------
  Control type              −0.36(−0.65,0.063)     −2.4    0.018   0.37      63.77           17.67
  Ethnicity                  0.35(−0.31,1.02)      1.07    0.29    0.45      67.72            1.06
  Sample size              −0.0036(−0.011,0.004)   −0.96   0.34    0.48      68.83           −5.23
  Method                     −0.12(−0.61,0.38)     −0.47   0.64    0.48      68.84           −6.17

10.1371/journal.pone.0060107.t003

###### Subgroup analysis.

![](pone.0060107.t003){#pone-0060107-t003-3}

                        NSCLC   Control                                    
  -------------------- ------- --------- ----- ------ ------ ------------- -------
  Sex                                                                      
  Male                   151      331     58    331    5.72   2.50--13.10     0
  Female                 34       88      11     88    5.74   2.41--13.70     0
  Race                                                                     
  Asia-pacific           972     2028     488   1903   3.23   2.37--4.40      0
  Caucasus               293      624     151   620    4.32   2.37--7.87      0
  Histology                                                                
  Sq                     228      348     151   332    2.81   1.96--4.05      0
  Ad                     224      421     140   421    2.53   1.85--3.44      0
  Other NSCLC            19       44       7     43    4.97   1.57--15.76   0.006
  Smoking status                                                           
  Nonsmoker               6       32       2     32    4.53   0.68--30.26   0.12
  Smoker                 84       220     24    209    7.28   3.89--13.62     0
  Stage                                                                    
  Early (I--II)          137      405     45    394    4.62   2.29--9.30      0
  Late (III--IV)         118      222     48    228    5.19   3.28--8.23      0
  Method                                                                   
  MSP                   1114     2294     569   2166   3.49   2.58--4.70      0
  RT-MSP                 70       142     25    142    5.58   1.64--18.94   0.006
  q-MSP                  81       216     45    216    2.44   1.07--5.54    0.033
  Control type                                                             
  Normal lung tissue     555     1363     155   1287   5.49   3.77--8.00      0
  Blood                  441      823     300   819    2.56   1.71--3.84      0
  Sputum                 205      357     126   287    1.49   0.86--2.57    0.151
  BALF                   64       109     58    130    2.97   1.16--7.65    0.024

Correlation of *P^16INK4A^* Gene Promoter Methylation between Tumor Tissue and Autologous Clinical Samples {#s3d}
----------------------------------------------------------------------------------------------------------

Generally, the frequency of *P^16INK4A^* promoter methylation ranged from 17% to 80% (median 44%) in the lung cancer tissue and 0 to 80% (median 15%) in the autologous controls according to the included studies. The methylation frequency in cancer tissue was much higher than that in clinical controls. We also find a strong and significant correlation between tumor tissue and autologous samples of *P^16INK4A^* promoter methylation across studies (Correlation coefficient 0.71, 95% CI:0.51--0.83, *P*\<0.0001,). [Fig. 4](#pone-0060107-g004){ref-type="fig"} demonstrates that most studies lie above the equal line between tumor tissue and controls, which illustrates the tumor tissue excess. In plasma samples, the methylation frequency ranged from 6% to 74% (median 33%), which showed a significant correlation of *P^16INK4A^* promoter methylation with cancer tissue (Correlation coefficient 0.72, 95% CI: 0.27--0.91, *P* = 0.0059, [Fig 5A](#pone-0060107-g005){ref-type="fig"}). The similar correlation was also found between the cancer tissue and sputum/BALF (Correlation coefficient 0.85, 95% CI: 0.35--0.97, *P* = 0.0082, [Fig. 5B](#pone-0060107-g005){ref-type="fig"}). The strong and significant correlation between tumor tissue and clinical autologous controls indicated that detection of methylation status in the clinical samples such as plasma, sputum or BALF can be a potential method for diagnosis of NSCLC without invasion.

![Methylation frequency in tumor tissue versus autologous controls.](pone.0060107.g004){#pone-0060107-g004}

![Correlation of *P^16INK4A^* promoter methylation between tumor tissue and autolougs clinical samples (A:plasm; B:BALF/sputum).](pone.0060107.g005){#pone-0060107-g005}

Publication Bias {#s3e}
----------------

A Begg's funnel plot and Egger's test were used to evaluate possible publication bias [@pone.0060107-Seike1]. As demonstrated in [Fig. 6](#pone-0060107-g006){ref-type="fig"}, the shape of the funnel plot showed a slight asymmetry at the bottom, with a trend towards reporting bigger odds ratio. However, Egger's test did not illustrate any evidence of statistical publication bias (t = 0.78, *P* = 0.44).

![Begg's funnel plot for assessment of publication bias.\
Each hollow circle represents a separate study for the indicated association. The area of the hollow circle reflects the weight (inverse of the variance). Horizontal line stands for the mean magnitude of the effect.](pone.0060107.g006){#pone-0060107-g006}

Discussion {#s4}
==========

Hypermethylation of CpG inlsnds in promoter regions is one of the important mechanisms for inactivation of tumor-suppressor genes, involving apoptosis, cell cycle, DNA repair and etc. Deregulation of the cell cycle control system was considered important in the procedure of tumorigenesis. *P^16INK4^* is known as one the most important tumor suppressor genes, which plays an important role in regulating the cell cycle. This gene generates several transcript variants that regulate the G1-S transition of the cell cycle [@pone.0060107-Liggett1]. In NSCLC, this gene product has been shown to be absence in about 32--70% of the cancer cells [@pone.0060107-Brambilla1], [@pone.0060107-Gazzeri1]. However, mutations of the *P^16INK4^* gene are only found to be 0--10% [@pone.0060107-Chen1], which indicating at least 22%--60% loss expression of *P^16INK4^* is associated with other mechanisms, including promoter hypermethylation.

In NSCLC, promoter hypermethylation of *P^16INK4a^* gene which encodes a cyclin-dependent kinase inhibitor, has been found in variety of studies with a frequency of 17% [@pone.0060107-Harden1] to 83% [@pone.0060107-Georgiou1] in the tumor tissue and 6% [@pone.0060107-Cirincione1] to 80% [@pone.0060107-Georgiou1] in autologous clinical samples. The frequency of aberrant methylation of this gene ranged from 6% [@pone.0060107-Ng1] to 74% [@pone.0060107-Liu2] in serum or plasma and 10% [@pone.0060107-Guo1] to 80% [@pone.0060107-Georgiou1] in sputum or BALF. Although many studies have reported the prevalence of *P^16INK4a^* gene methylation in NSCLC, the association between cancer tissue and autologous clinical samples was not definitive with the reasons of small sample size. Thus, a meta-analysis was performed to quantify the methylation-disease association, by pooling data from published studies, which can increase the statistical power.

In the present study, we included a total of thirty-four articles that reported data of methylation frequency in non-small cell lung carcinoma tissue and autologous samples. The frequency of *P^16INK4A^* promoter methylation ranged from 17% to 80% (median 44%) in the lung cancer tissue and 0 to 80% (median 15%) in the autologous controls, which shows a great variety of methylation rate between studies. In general, the pooled odds ratio of methylation was 3.45 (95% CI: 2.63--4.54) in tumor tissue versus autologous samples under random-effect method, indicating the *P^16INK4A^* promoter methylation plays an important role in the tumorigenesis of NSCLC.

In subgroup analysis, the methylation odds in tumor tissue ranged from 1.49(0.86--2.57) to 5.49(3.77--8.00) when comparing to different autologous sample sets (non-tumor lung tissue, plasma, sputum and BALF). The methylation odds in tumor tissue was not significant when comparing to sputum (*P* = 0.151) indicating no statistical different frequency of *P^16INK4A^* promoter methylation was observed between sputum and cancer tissue in non-small cell lung cancer patients. However, the results should be interpreted with caution as only a small subject was included in sputum control subgroup analysis. In other subgroups, the methylation odds in tumor tissue ranged from 2.53 (1.85--3.44) to 7.28(3.89--13.62) according to clinical characteristics such as sex, ethnicity, histology, smoking status and stages. And the highest odds 7.28(3.89--13.62) in tumor tissue was found in smokers, demonstrating smoking may play an important role in the methylation of *P^16INK4A^* promoter regions, which was in accordance with previous studies [@pone.0060107-Zhang5]. The lowest odds 2.53(1.85--3.44) in tumor tissue was shown in the adenocarcinoma, suggesting the influence of *P^16INK4A^* promoter methylation was reduced in this kind of histology type.

Generally, a strong and significant correlation between tumor tissue and autologous samples in *P^16INK4A^* promoter methylation was found across studies(Correlation coefficient 0.71, 95% CI: 0.51--0.83, *P*\<0.0001), which suggested the higher frequency of methylation in autologous sample was found, the higher prevalence of methylation can be observed in cancer tissue in patients with NSCLC. And this indicated that detection of methylation status in autologous samples such as plasma, sputum or BALF can be a potential method for diagnosis of NSCLC without invasion. And according to Esteller [@pone.0060107-Esteller1], the detection of promoter hypermethylaiton in tumor suppressor genes had important clinical use, such as diagnostic tool, biomarker for prognosis, predictor for treatment responses and etc.

However, several limitations required consideration of this study. The first limitation is heterogeneity. In this meta-analysis a significant heterogeneity was existed between studies (I^2^ = 69.8%, χ^2^ = 135.7, *P*\<0.0001). Although, the meta-regression was performed for further evaluation of the source of heterogeneity with the Knapp-Hartung modification method, complete data can only be obtained in the subtypes of control types, ethnicity, sample size and methylation detection methods. In the results of the meta-regression, only a small part of heterogeneity can be explained by different ethnicity, sample size and methylation detection methods, indicating that some other source of heterogeneity must be exist among studies. Second, although no evident of publication bias was found in this study by Egger's test, the small number of studies and possible existence of unpublished articles are inevitable and completely ruling out this possibility in all aspects is difficult [@pone.0060107-Trinquart1]. The third limitation is the co-variate analysis of methylation. Demonstrating by the previous studies, promoter hypermethylation was associated with many clinical, demographic and molecular features, such as gender, age, smoking status and ethnicity [@pone.0060107-Hsu1], [@pone.0060107-Georgiou1], [@pone.0060107-Kim1]. And methylation events themselves may also be linked and interact with each other, suggesting methylation analysis of a single gene may be far from enough [@pone.0060107-Taby1]. Fourth, as known that the promoter methylation is correlated with the reduction of gene expression. However, only three articles included in this meta-analysis provided the *P^16^* gene expression status by using immunohistochemical analysis. The individual patient data (IPD) for the relationship between methylation status and expression of this gene was not given in the original articles. For the *P^16INK4A^* mutation, with carefully examination of the included studies, we found only two studies [@pone.0060107-Seike1], [@pone.0060107-Chen1] reported the *P^16INK4A^* mutation in exon 1, 2a and 2b regions. And none of the included 34 articles reported the mutation status of *P^16INK4A^* in promoter region.

In conclusion, the results of this study showed a higher prevalence of methylation in tumor tissue versus autologous samples in NSCLC patients, which demonstrate promoter methylation plays an important role in carcinogenesis. And the significant correlation between tumor tissue and clinical controls of *P^16INK4A^* gene promoter methylation indicated a promising biomarker for NSCLC diagnosis. However, significant methodological and validation issues remain to be addressed to provide the data that will enable this information to be considered for further clinical use [@pone.0060107-Sapari1].
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